Teva announces new positive AJOVY®▼ (fremanezumab) real world data from its migraine prevention study, PEARL and welcomes updated European Headache Federation guidelines on the use of CGRP mAbs
PharmiWeb,
Real-world observational study data presented at Migraine Trust International Symposium (MTIS) demonstrate sustained…